ACH
NGNE icon

ArrowMark Colorado Holdings’s Neurogene NGNE Stock Holding History

ArrowMark Colorado Holdings’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.8M Sell
342,453
-182,343
-35% -$5.02M 0.45% 77
2026
Q1 		$10.6M Sell
524,796
-52,694
-9% -$1.02M 0.28% 112
2025
Q4 		$11.9M Sell
577,490
-18,349
-3% -$457K 0.26% 112
2025
Q3 		$10.3M Buy
595,839
+10,442
+2% +$210K 0.19% 132
2025
Q2 		$8.75M Buy
585,397
+143,806
+33% +$2.26M 0.16% 135
2025
Q1 		$5.17M Sell
441,591
-7,010
-2% -$122K 0.08% 174
2024
Q4 		$10.3M Buy
448,601
+62,136
+16% +$2.31M 0.14% 135
2024
Q3 		$16.2M Hold
386,465
– – 0.21% 107
2024
Q2 		$14.1M Sell
386,465
-51,073
-12% -$1.8M 0.17% 116
2024
Q1 		$22.3M Sell
437,538
-87,991
-17% -$2.94M 0.25% 94
2023
Q4 		$10.2M Buy
+525,529
New +$7.53M 0.11% 143

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

ArrowMark Colorado Holdings's NGNE Position: Q2 2026 in Review

ArrowMark Colorado Holdings reduced its Neurogene (NGNE) stake by 35% in Q2 2026, selling an estimated $5.02M and leaving 342,453 shares worth $10.8M. The position accounts for 0.45% of the portfolio, ranked #77.

ArrowMark Colorado Holdings first reported a position in NGNE in Q4 2023 and has held it in 11 quarters since. The position peaked at $22.3M in Q1 2024. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • ArrowMark Colorado Holdings held 342,453 shares of Neurogene worth $10.8M as of Q2 2026.
  • ArrowMark Colorado Holdings sold 182,343 Neurogene shares in Q2 2026, an estimated $5.02M.
  • Neurogene made up 0.45% of ArrowMark Colorado Holdings's portfolio in Q2 2026, its #77 holding.
  • ArrowMark Colorado Holdings first reported a position in Neurogene in Q4 2023 and has held it in 11 quarters since.
  • ArrowMark Colorado Holdings's Neurogene position peaked at $22.3M in Q1 2024.
  • 112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on ArrowMark Colorado Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.